JP2018519277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519277A5 JP2018519277A5 JP2017564426A JP2017564426A JP2018519277A5 JP 2018519277 A5 JP2018519277 A5 JP 2018519277A5 JP 2017564426 A JP2017564426 A JP 2017564426A JP 2017564426 A JP2017564426 A JP 2017564426A JP 2018519277 A5 JP2018519277 A5 JP 2018519277A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- carboxylic acid
- bone
- group
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175118P | 2015-06-12 | 2015-06-12 | |
| US62/175,118 | 2015-06-12 | ||
| PCT/IB2016/053482 WO2016199111A1 (en) | 2015-06-12 | 2016-06-13 | Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519277A JP2018519277A (ja) | 2018-07-19 |
| JP2018519277A5 true JP2018519277A5 (enExample) | 2020-04-30 |
| JP7174982B2 JP7174982B2 (ja) | 2022-11-18 |
Family
ID=57503230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564426A Active JP7174982B2 (ja) | 2015-06-12 | 2016-06-13 | アミド連結ｅｐ４アゴニスト－ビスホスホネート化合物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10400000B2 (enExample) |
| EP (1) | EP3307747A4 (enExample) |
| JP (1) | JP7174982B2 (enExample) |
| CN (1) | CN107849072B (enExample) |
| WO (1) | WO2016199111A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
| CN107849072B (zh) | 2015-06-12 | 2020-12-15 | 西蒙弗雷泽大学 | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 |
| US20250295725A1 (en) * | 2022-01-14 | 2025-09-25 | Purdue Research Foundation | Bone targeted treatment in osteogenesis imperfecta |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
| WO2026013441A1 (en) * | 2024-07-10 | 2026-01-15 | Mesentech Inc. | Bisphosphonate-ep4 agonists for selective delivery to damaged muscle |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3224995A (en) * | 1961-02-16 | 1965-12-21 | Ethyl Corp | Polyvinyl chloride plasticized with dialkoxyalkyl homoterephthalates |
| US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
| JPS6034971A (ja) * | 1984-07-23 | 1985-02-22 | Sangyo Kagaku Kenkyu Kyokai | 抗菌性組成物 |
| DE3827836C1 (enExample) | 1988-08-17 | 1989-10-19 | Eduard Kuesters, Maschinenfabrik, Gmbh & Co Kg, 4150 Krefeld, De | |
| US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
| US5510517A (en) | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| TW257765B (enExample) | 1993-08-25 | 1995-09-21 | Merck & Co Inc | |
| JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
| EP1114816A4 (en) | 1998-09-14 | 2002-09-04 | Ono Pharmaceutical Co | SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT |
| US6121253A (en) | 1998-11-20 | 2000-09-19 | Merck Frosst Canada & Co. | Prostaglandin conjugates for treating or preventing bone disease |
| AP2002002555A0 (en) | 1999-12-22 | 2002-06-30 | Pfizer Prod Inc | EP4 Receptor selective agonists in the treatment of osteoporosis. |
| ATE327751T1 (de) | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz |
| WO2001072268A1 (en) | 2000-03-31 | 2001-10-04 | Toray Industries, Inc. | Hair growth or hair formation controlling agents |
| AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| EA200300379A1 (ru) | 2000-11-27 | 2003-08-28 | Пфайзер Продактс Инк. | Селективные агонисты рецептора ep4 в лечении остеопороза |
| WO2003047417A2 (en) | 2001-12-03 | 2003-06-12 | Merck & Co., Inc. | Ep4 receptor agonist, compositions and methods thereof |
| EP1513589B1 (en) | 2002-06-06 | 2010-11-10 | Merck Frosst Canada Ltd. | 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma |
| CA2487977A1 (en) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
| JP2006504679A (ja) | 2002-08-28 | 2006-02-09 | メルク フロスト カナダ アンド カンパニー | 緑内障の治療においてｅｐ４受容体作動薬として使用するためのオキサゾリジン−２−オンおよびチアゾリジン−２−オン誘導体 |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| US7560589B2 (en) | 2003-07-28 | 2009-07-14 | Smithkline Beecham Corporation | Cycloalkylidene compounds as modulators of estrogen receptor |
| WO2005116010A1 (en) | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
| US7772392B2 (en) * | 2005-05-06 | 2010-08-10 | Allergan, Inc. | Therapeutic substituted β-lactams |
| US20070232660A1 (en) | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| JP2010513551A (ja) | 2006-12-18 | 2010-04-30 | アラーガン インコーポレイテッド | 胃腸疾患の治療方法および組成物 |
| CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
| WO2012102355A1 (ja) * | 2011-01-27 | 2012-08-02 | 小野薬品工業株式会社 | 二環式化合物およびその医薬用途 |
| WO2014078446A2 (en) | 2012-11-16 | 2014-05-22 | Allergan, Inc. | Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations |
| US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
| CN107849072B (zh) | 2015-06-12 | 2020-12-15 | 西蒙弗雷泽大学 | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 |
-
2016
- 2016-06-13 CN CN201680038591.9A patent/CN107849072B/zh active Active
- 2016-06-13 US US15/735,372 patent/US10400000B2/en active Active
- 2016-06-13 WO PCT/IB2016/053482 patent/WO2016199111A1/en not_active Ceased
- 2016-06-13 JP JP2017564426A patent/JP7174982B2/ja active Active
- 2016-06-13 EP EP16807008.4A patent/EP3307747A4/en active Pending
-
2019
- 2019-07-22 US US16/518,132 patent/US11312737B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3984164B2 (ja) | 骨粗鬆症治療用ｅｐ４受容体選択的アゴニスト | |
| US10034890B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| US9884069B2 (en) | Osteoclast inhibitors for knee conditions | |
| US10080765B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
| US9956234B2 (en) | Osteoclast inhibitors for joint conditions | |
| US9827192B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| US10028908B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| Otto et al. | Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? | |
| JP2013531627A5 (enExample) | ||
| US7285572B2 (en) | CaSR antagonist | |
| JP5492564B2 (ja) | ビスホスホネートの水性懸濁液を含む長期徐放性医薬組成物 | |
| US20170143747A1 (en) | Compositions for administration of zoledronic acid or related compounds for treating low back pain | |
| US20170304331A1 (en) | Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain | |
| US20180133232A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| US20180064734A1 (en) | Neridronic acid for treating complex regional pain syndrome | |
| HU211317A9 (en) | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids | |
| JP2010513483A5 (enExample) | ||
| US11667630B2 (en) | Nitrogen-containing 6-membered cyclic compound | |
| Siddiqi et al. | Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma? | |
| CN107849072B (zh) | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 | |
| JP2008528617A5 (enExample) | ||
| ATE307811T1 (de) | Triazole für die behandlung von auf die modulation des dopamin d3 rezeptors ansprechende krankheiten | |
| NZ738016B2 (en) | Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof | |
| Ferrara et al. | Etiopathogenesis and Clinical Aspects of BIONJ | |
| WO2015159153A1 (en) | Novel bisphosphonates and their use |